Pharmanutra Forecast, price target & analysts
Pharmanutra Target price 2026 - Analyst rating & recommendation
Pharmanutra Classifications & Recommendation
Pharmanutra Price Target
| Target Price | €94.86 |
| Price | €71.30 |
| Potential | |
| Number of Estimates | 4 |
| 4 Analysts have issued a price target Pharmanutra 2027 . The average Pharmanutra target price is €94.86. This is higher than the current stock price. The highest price target is , the lowest is . | |
| A rating was issued by 7 analysts: 6 Analysts recommend Pharmanutra to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Pharmanutra stock has an average upside potential 2027 of . Most analysts recommend the Pharmanutra stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million € | ??? | ??? |
| ??? | ??? | |
| EBITDA Margin | ??? | ??? |
| ??? | ??? | |
| Net Margin | ??? | ??? |
| ??? | ??? |
4 Analysts have issued a sales forecast Pharmanutra 2026 . The average Pharmanutra sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
4 Analysts have issued an Pharmanutra EBITDA forecast 2026. The average Pharmanutra EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
4 Pharmanutra Analysts have issued a net profit forecast 2026. The average Pharmanutra net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | ??? | ??? |
| ??? | ??? | |
| P/E | ??? | |
| EV/Sales | ??? |
Current Pharmanutra Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| Analyst Rating | Date |
|---|---|
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
